We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
RTI Surgical Now Part of US-Based Manufacturing Initiative
Read MoreHide Full Article
Headquartered in Alachua, FL, RTI Surgical, Inc. a global developer, manufacturer and provider of orthopedic and other surgical implants, recently announced that it is now part of a U.S. public-private Manufacturing initiative, the Advanced Regenerative Manufacturing Institute (ARMI).
Stock Performance
RTI Surgical has had an impressive run on the bourse on a year-to-date basis. The company gained roughly 63.08%, which is higher than the Zacks categorized Medical instruments sub-industry’s gain of almost 17.89%.
The current level compares favorably with the S&P 500’s return of 11.19% over the same time frame, along with a long-term expected earnings growth rate of 15.00% which instills confidence in investors. RTI Surgical currently carries a Zacks Rank #3 (Hold).
Coming back to the news, headquartered in Manchester, NH, ARMI is the 12th Manufacturing U.S. institute. It brings together a consortium of nearly 100 partner organizations from industry, government, academia and the non-profit sector to develop next-generation manufacturing processes and technologies for cells, tissues and organs. ARMI’s efforts are supported by 47 industrial partners, 26 academic and academically affiliated partners, and 14 government and non-profit partners.
The consortium will combine approximately $80 million grant from the federal government, alongside $200 million in cost share from partner organizations, to support the development of tissue and organ manufacturing capabilities. This would be part of the efforts to revitalize American manufacturing and incentivize companies to invest in new technology development in the U.S. ARMI will lead the Advanced Tissue Biofabrication (ATB) Manufacturing USA Institute, on behalf of the Department of Defense.
ARMI will work under the umbrella of Manufacturing USA, a public-private network, that invests in the development of advanced manufacturing technologies.
Looking forward, we are upbeat on RTI Surgical’s leading position in synthetic-based implants. The company is currently focusing on ‘tracking and tracing of tissue implants’. The latest development is expected to enhance tissue transplantation trends and have path-breaking impact in the days to come.
RTI Surgical is gaining prominence on the back of the recent string of regulatory approvals. NanOss Bioactive bone void filler, an advanced bone graft substitute of the company, got approved by the Australian Therapeutic Goods Administration. The company has also announced CE Mark approval for nanOss Bioactive Loaded bone void filler and nanOss Bioactive 3D bone void filler in Europe.
Key Picks
Better-ranked stocks in the broader medical sector include Luminex Corporation , Edwards Lifesciences Corp. (EW - Free Report) and Accelerate Diagnostics, Inc (AXDX - Free Report) . Luminex sports a Zacks Rank #1 (Strong Buy), while Edwards Lifesciences and Accelerate Diagnostics carry a Zacks Rank #2 (Buy). You can seethe complete list of today’s Zacks #1 Rank stocks here.
Luminex has an expected long-term adjusted earnings growth of almost 16.3%. The stock added roughly 7.1% over the last three months.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.6%. The stock has a solid one-year return of around 13.6%.
Accelerate Diagnostics projects long-term adjusted earnings growth of almost 30%. The stock returned 30.9% over the last one year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
RTI Surgical Now Part of US-Based Manufacturing Initiative
Headquartered in Alachua, FL, RTI Surgical, Inc. a global developer, manufacturer and provider of orthopedic and other surgical implants, recently announced that it is now part of a U.S. public-private Manufacturing initiative, the Advanced Regenerative Manufacturing Institute (ARMI).
Stock Performance
RTI Surgical has had an impressive run on the bourse on a year-to-date basis. The company gained roughly 63.08%, which is higher than the Zacks categorized Medical instruments sub-industry’s gain of almost 17.89%.
The current level compares favorably with the S&P 500’s return of 11.19% over the same time frame, along with a long-term expected earnings growth rate of 15.00% which instills confidence in investors. RTI Surgical currently carries a Zacks Rank #3 (Hold).
Coming back to the news, headquartered in Manchester, NH, ARMI is the 12th Manufacturing U.S. institute. It brings together a consortium of nearly 100 partner organizations from industry, government, academia and the non-profit sector to develop next-generation manufacturing processes and technologies for cells, tissues and organs. ARMI’s efforts are supported by 47 industrial partners, 26 academic and academically affiliated partners, and 14 government and non-profit partners.
The consortium will combine approximately $80 million grant from the federal government, alongside $200 million in cost share from partner organizations, to support the development of tissue and organ manufacturing capabilities. This would be part of the efforts to revitalize American manufacturing and incentivize companies to invest in new technology development in the U.S. ARMI will lead the Advanced Tissue Biofabrication (ATB) Manufacturing USA Institute, on behalf of the Department of Defense.
ARMI will work under the umbrella of Manufacturing USA, a public-private network, that invests in the development of advanced manufacturing technologies.
Looking forward, we are upbeat on RTI Surgical’s leading position in synthetic-based implants. The company is currently focusing on ‘tracking and tracing of tissue implants’. The latest development is expected to enhance tissue transplantation trends and have path-breaking impact in the days to come.
RTI Surgical is gaining prominence on the back of the recent string of regulatory approvals. NanOss Bioactive bone void filler, an advanced bone graft substitute of the company, got approved by the Australian Therapeutic Goods Administration. The company has also announced CE Mark approval for nanOss Bioactive Loaded bone void filler and nanOss Bioactive 3D bone void filler in Europe.
Key Picks
Better-ranked stocks in the broader medical sector include Luminex Corporation , Edwards Lifesciences Corp. (EW - Free Report) and Accelerate Diagnostics, Inc (AXDX - Free Report) . Luminex sports a Zacks Rank #1 (Strong Buy), while Edwards Lifesciences and Accelerate Diagnostics carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Luminex has an expected long-term adjusted earnings growth of almost 16.3%. The stock added roughly 7.1% over the last three months.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.6%. The stock has a solid one-year return of around 13.6%.
Accelerate Diagnostics projects long-term adjusted earnings growth of almost 30%. The stock returned 30.9% over the last one year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>